Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust - PANEL

03 December 2013

09:45 to 10:30 Local Event Time (BST)



With recent surveys revealing pharmaceutical companies now ranking in trust perceptions below producers of spirits and tobacco, and physicians basing prescribing decisions as much on brands as on products, the need for pharmaceutical companies to understand and address the factors contributing to poor reputation has never been greater. How can pharma companies restore reputation and increase trust? What role can transparency play? How can social media be harnessed to improve reputation amongst partners and patients? What is the patient’s view of value in pharma?

Loading video...
You need the Adobe Flash Player to see this content.


  • Andrew Jack
    Pharmaceutical Correspondent
    Financial Times
    United Kingdom
  • William Burns
    Former Chief Executive, Pharmaceuticals
    Roche / Independent Director on several Boards
  • Nikos Dedes
    Chair / Member
    Positive Voice, Greece / EMA Management Board
  • Marijn Dekkers
    Chairman of the Board of Management
  • Rogier Snijdewind
    Adviser, Responsible Investment
    PGGM Investment